Moreover, if the health public service continues to stand against whole genome screening, people will soon turn to private companies, that can already provide this kind of services. This policy will thus increase the risk of incomplete or misleading interpretations without any kind of support from medical stuff.
The topic of genomic risk assessment in healthy people has been recently discussed also on the New England Jornal of Medicine, that published a review on clinical whole exome and whole genome sequencing. The journal also presented the hypothetical scenario of a subject which discovers some cancer affected relatives and wants to undergo genetic testing. They propose 2 strategies, gene panel or whole exome/genome sequencing and the case is open for readers to comment with even a pool to vote for your preferred solution.